Jagsonpal Pharmaceuticals (JAGSNPHARM) Investor presentation summary

Strategic rationale and acquisition overview

• Acquired the wellness portfolio of Group Pharmaceuticals, adding a consumer wellness pillar to the existing Rx franchise and supporting the INR 500 Cr topline ambition.

• Acquisition brings two key brands with FY26 revenue of ~INR 24.6 Cr, expanding the Rx-branded generics portfolio and strengthening presence in six states.

• Transaction structured with ~50% deferred payments, preserving liquidity and aligning future performance with consideration.

• Acquisition is margin accretive and creates a scalable platform for future growth, with cross-selling opportunities and deeper doctor reach.

• Supported by a strong balance sheet with cash reserves exceeding INR 100 Cr, enabling continued inorganic expansion.

Integration, synergies, and value creation

• Integration of Group Pharma’s brands and field force with the existing network unlocks untapped markets and accelerates brand productivity.

• Cross-selling acquired brands through the expanded field force and doctor base is expected to drive incremental volumes.

• Cost synergies anticipated across supply chain, procurement, and distribution, enhancing operating leverage.

• Proven M&A playbook demonstrated with prior acquisitions (Yash Pharma, Aequitas Healthcare), each adding new capabilities and channels.

• Financial discipline maintained through lean working capital and judicious cash management.

Financial and operational performance

• Q1FY27 revenue grew 9%, operating EBITDA rose 21%, and PAT expanded 22%, reflecting strong operating leverage.

• Wellness portfolio’s FY26 net revenue was ~INR 24.6 Cr, with gross margins of 78.1% in H1 FY27E.

• Company-wide FY22-26 PAT grew 2.4x, cash balance 2.5x, and FCF 8x, with a 7.2% revenue CAGR and 24.9% EBITDA CAGR.

• Asset-light model with outsourced R&D and manufacturing supports scalable growth without capital strain.

• Cash balance of ~INR 170 Cr as of Q1FY27 supports future inorganic opportunities.